[1S02m-02] Off-the-Shelf Chimeric Antigen Receptor (CAR) T Cells Derived from Induced Pluripotent Stem Cells (iPSC) for Allogeneic Cancer Immunotherapy

^○Yoshiaki Kassai^1,2, Shoichi Iriguchi^2,3, Yutaka Yasui³, Yohei Kawai³, Mihoko Kunitomo^1,2, Kazuhide Nakayama^1,2, Takayuki Satou^1,2, Maiko Takiguchi^1,2, Suguru Arima^1,2, Tatsuki Ueda³, Atsutaka Minagawa³, Yuta Mishima³, Nariaki Yanagawa³, Yuji Baba¹, Yasuyuki Miyake^2,3, Tokuyuki Shinohara^1,2, Xi Shi¹, Yu Qian¹, Jianxin Hu¹, Alisha Bothun¹, Qiong Xue¹, Lan Cao¹, Akira Hayashi^1,2, Shin Kaneko^2,3 (1.T-CiRA Discovery, Takeda Pharmaceutical Company, Ltd., 2.Takeda-CiRA Joint Program (T-CiRA), 3.Shin Kaneko Laboratory, Department of Cell growth and Differentiation, Center for iPS cell research and application (CiRA), Kyoto University)

キーテクノロジー：iPSC

Chimeric antigen receptor、iPSC、cancer immunotherapy